Shape effect in active targeting of nanoparticles to inflamed cerebral endothelium under static and flow conditions by Silva Candal, Andrés da et al.
Contents lists available at ScienceDirect
Journal of Controlled Release
journal homepage: www.elsevier.com/locate/jconrel
Shape effect in active targeting of nanoparticles to inflamed cerebral
endothelium under static and flow conditions
A. Da Silva-Candala,⁎, T. Brownb, V. Krishnanb, I. Lopez-Loureiroa, P. Ávila-Gómeza, A. Pusulurib,
A. Pérez-Díazc, C. Correa-Paza, P. Hervellaa, J. Castilloa, S. Mitragotrib,⁎, F. Camposa,⁎
a Clinical Neurosciences Research Laboratory, Clinical University Hospital, Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain
b John A. Paulson School of Engineering and Applied Sciences Wyss Institute, Harvard University, Cambridge, MA, 02138, United States of America
c Drug Screening Platform/Biofarma Research Group, Molecular Medicine and Chronic Diseases Research Center, University of Santiago de Compostela, Santiago de
Compostela, Spain






A B S T R A C T
Endothelial cells represent the first biological barrier for compounds, including nanoparticles, administered via
the intravascular route. In the case of ischemic stroke and other vascular diseases, the endothelium over-
expresses specific markers, which can be used as molecular targets to facilitate drug delivery and imaging.
However, targeting these markers can be quite challenging due to the presence of blood flow and the associated
hydrodynamic forces, reducing the likelihood of adhesion to the vessel wall. To overcome these challenges,
various parameters including size, shape, charge or ligand coating have been explored to increase the targeting
efficiency. Geometric shape can modulate nanoparticle binding to the cell, especially by counteracting part of
the hydrodynamic forces of the bloodstream encountered by the classical spherical shape. In this study, the
binding affinity of polystyrene nanoparticles with two different shapes, spherical and rod-shaped, were com-
pared. First, vascular adhesion molecule-1 (VCAM-1) was evaluated as a vascular target of inflammation, in-
duced by lipopolysaccharide (LPS) stimulation. To evaluate the effect of nanoparticle shape on particle adhesion,
nanoparticles were coated with anti-VCAM-1 and tested under static conditions in cell culture dishes coated with
cerebral microvasculature cells (bEnd.3) and under dynamic flow conditions in microfluidic channels lined with
hCMEC/D3 cells. Effect of particle shape on accumulation was also assessed in two in vivo models including
systemic inflammation and local brain inflammation. The elongated rod-shaped particles demonstrated greater
binding ability in vitro, reaching a 2.5-fold increase in the accumulation for static cultures and 1.5-fold for flow
conditions. Anti-VCAM-1 coated rods exhibited a 3.5-fold increase in the brain accumulation compared to
control rods. These results suggest shape offers a useful parameter in future design of drug delivery nanosystems
or contrast agents for neurovascular pathologies.
1. Introduction
Intravenous (i.v.) administration is one of the most common clinical
routes for administering drugs, allowing for their rapid distribution
throughout the body. However, this form of administration can lead to
non-specific, often toxic, off-target effects and can require the use of
high drug doses to achieve the therapeutic effect [1,2]. The possibility
of encapsulating pharmaceuticals within carriers has made nanomedi-
cine a promising approach for treating several diseases by localizing the
drug at the therapeutic site.
Vascular endothelium has been widely explored as a therapeutic
target of nanoparticles, primarily for inflammatory pathologies [3,4]. In
response to local pro-inflammatory stimuli, the endothelial expression
of cell adhesion molecules is upregulated to mediate interactions with
immunological cells [5]. This allows for leukocyte adhesion to the en-
dothelium, followed by extravasation at the site of inflammation [5].
The specific upregulation of inflammatory-mediated vascular proteins
(e.g; ICAM-1 and VCAM1) has been used for targeting not only drug
carriers [6,7], but also imaging agents [8].
Important physical parameters that can affect the success of nano-
particles in reaching their target in the vascular endothelium include
blood flow rate and vessel tortuosity. Several aspects can be modified
during the design of a nanoparticle that can improve the binding rate
after in vivo administration, such as size, shape, and charge. The ideal
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combination of these factors can determine the success of the binding to
the cellular target [9]. Overall, particle geometry is a key parameter for
vascular targeting [10]. Specifically, rod shaped particles have shown
significant improvements over spherical particles [11]. The influence of
shape on the binding affinity of nanoparticles with vascular endothelial
cells has been studies through experimental and theoretical analyses
[9,12,13]. These studies have identified several key variables including
hydrodynamic forces, distance between nanoparticle and target-pro-
tein, target-protein density, and the contact area between the nano-
particle and the cell [14]. Rod-shaped particles have been particularly
thought to benefit via improved contact area with the target compared
to spherical nanoparticles [15]. In this work, we analyze the effect of
nanoparticle shape when targeted to inflammatory vascular markers in
vitro under static and dynamic flow conditions along with in vivo dy-
namic conditions.
2. Materials and methods
2.1. Preparation of rod-shaped nanoparticles
Rod-shaped particles were prepared using the film stretching
method as described in previous reports using commercially-available
spherical Fluoresbrite® Yellow-Orange Carboxylate polystyrene parti-
cles of 200 nm in diameter (Polysciences, PA, USA) [16]. Polyvinyl
alcohol (PVA) films were first made by dissolving 5 g of PVA-hot water-
soluble grade (Sigma-Aldrich, MO, USA) in 80mL of water at 130 °C
with constant stirring. Glycerol (1 mL) (Sigma-Aldrich, MO, USA) was
added as a plasticizer. The PVA-glycerol solution was allowed to cool to
room temperature before adding the particles. The mixture was cast on
a flat surface (25cm2) and allowed to solidify overnight. Formed films
were cut and clamped in a proprietary stretching apparatus before
being placed in a heated oil bath (120 °C) for 5min. The film was then
stretched to the desired dimensions for two-aspect ratio particles.
Stretched particle-embedded films were dissolved in water overnight
and purified by centrifugation. Particle morphology was characterized
with a FEI XL30 Sirion FEG SEM Scanning electron microscopy (SEM).
For particle functionalization, 1mg of each particle shape was di-
luted in 1mL 0.5 mM of 2-(N-morpholino) ethanesulfonic acid (MES)
buffer to a pH 4.7 and the same mass (1 mg) of N-(3-
Dimethylaminopropyl)-N-ethylcarbodiimide (EDC) and N-
Hydroxysuccinimide (NHS) was added to the mixture an activated for
15min, then 0.5 mg of 3 K length polyethyleneglycol with a terminal
azide group (NH2-PEG-N3) was added and allowed to react (all products
Sigma-Aldrich, MO, USA). For PEG quantification experiments 0.5mg
of fluorescent PEG (NH2-PEG-FITC) were used instead (Nanocs, Ny,
USA). Two different antibodies were coupled to the nanoparticles re-
garding the group, anti-VCAM-1 antibody for targeted particles, and a
non-specific IgG antibody for the vehicle group. For this, 50 μg of an-
tibody was added to PBS to a concentration of 6.7 μM, then added
20mM sodium periodate (NaIO4) (Sigma-Aldrich, USA) for 45min. The
oxidation was stopped by adding ethylene glycol (Sigma-Aldrich, USA)
followed by PBS washing in 3 kDa-pore filters (Amicon Ultra 3 k, Merck,
USA). A 10× (with respect to the antibody molarity) amine DBCO
solution was added and allowed to react for 24 h at room temperature.
The non-reacted DBCO was removed by filtration. Finally, the antibody-
DBCO solution was added to 1mg of pegylated particles and allowed to
react for 24 h at room temperature. Particle's zeta potential was mea-
sured by means of dynamic light scattering (Zetasizer Nano ZS, Malvern
Panalytical, MA, USA).
For in vivo biodistribution the particles were coated with a tritiated
glycine molecule (Glycine, [2−3H]-, 1 mCi-37MBq, Perkinelmer, USA)
prior to pegylation. The coupling was performed through and EDC/NHS
reaction (same ratios and times as described above). Nanoparticle
suspension was brought to a pH of 9.7 and 4 μL of 3H-Glycine (1mC/
mL) was immediately added. It was kept in agitation at room tem-
perature for 24 h and it was washed by centrifugation at 21,000×g at
room temperature until the supernatants obtained had no radiation
present.
2.2. Experimental animals
The experimental protocols were approved by the University
Clinical Hospital of Santiago de Compostela Animal Care Committee,
according to the European Union (EU) rules (86/609/ CEE, 2003/65/
CE, and 2010/63/EU) and as per the ARRIVE guidelines. Male Swiss
mice weighing 30 g were used for this study. Mice were provided ad
libitum access to food and water. Anesthesia was induced with sevo-
flurane (5–6% for induction and 3–4% for maintenance) evaporated in
an oxygen–air mixture (30%:70%). Throughout the surgical period,
rectal temperature was maintained at 37 ± 0.5 °C by means of an
electronic thermostat-controlled warming blanket. Body temperature
was maintained until animals completely recovered from anesthesia
and displayed normal motor activity.
2.3. Experimental design
To evaluate the shape effect on binding affinity of nanoparticles, a
total of four groups were tested: i) spheres coated with anti-VCAM-1
(targeted spheres) ii) spheres coated with a non-specific IgG antibody
(vehicle spheres), iii) rods coated with anti-VCAM-1 (targeted rods) and
iv) rods coated with a non-specific IgG (vehicle rods). The four nano-
particle groups were tested in four different experimental conditions: i)
static in vitro cell culture, ii) in vitro flow conditions, iii) in vivo systemic
inflamed mice and iv) in vivo intracerebrally inflamed mice.
2.4. Static in vitro cell culture nanoparticle accumulation
BEnd.3 microvasculature brain endothelial cells (ATCC, VA, USA)
were cultured in Dulbecco's Modified Eagle Medium (DMEM), with
10% (v/v) of fetal bovine serum (FBS) and 0.1% (v/v) of penicillin-
streptomycin, expanded in T75 flask (Corning, NY, USA), and incubated
at 37 °C with a humidified atmosphere containing 95% air and 5% of
CO2. Media was replaced every 3 days until 80% of confluence was
reached. Then, cells were detached with of 0.25% trypsin-EDTA (Gibco-
Invitrogen, MA, USA), trypsin was blocked with 6mL of complete
medium (with FBS) and centrifuged for 5min at 200×g. The pellet
formed was resuspended in phosphate buffered saline (PBS) and cen-
trifuged again. Cells were then seeded in 24-well plates and incubated
under the same conditions until reaching the 80% of confluence to
perform the subsequent experiments.
2.4.1. Cell inflammation induction
Inflammation induction in bEnd.3 (mouse) and hCMEC/d3 (human)
endothelial cell cultures was performed using LPS of E. coli (O111:B4,
Sigma-Aldrich, MO, USA) over a period of 6 h at a concentration of
1 μg/mL. Analysis of VCAM-1 and ICAM-1 expression was determined
by immunohistology and flow cytometry to test the LPS-mediated in-
flammation effect.
2.4.2. Cell histological analysis
Cells were incubated with Paraformaldehyde (PFA) 4% (Sigma-
Aldrich, MO, USA) for 10min. Then incubated with a solution of PBS
with 0.01% (v/v) Tween 20 (PBS-T), 1:200 anti-VCAM-1 monoclonal
antibody (Biolegend, CA, USA) and a 5% (v/v) of donkey serum (Sigma-
Aldrich, MO, USA) for 24 h at 4 °C. The unbound antibody was removed
with 3 washes with PBS. Then, cells were incubated with a solution of
PBS-T a 1:400 Alexa Fluor®anti-rat 594 secondary antibody (Thermo-
Fischer, MA, USA) with 5% of donkey serum for 2 h at 4 °C. Cells were
washed again and incubated with a solution of PBS-T and 1:6,000
Hoechst (Invitrogen, CA, USA) for 5min at room temperature for nu-
clear staining and washed again. Aqua Polymount (Polysciences, CA,
USA) was added to each well and kept in the dark at room temperature
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for 2 h until it dried up. Samples were stored at 4 °C until imaging. The
staining process was also performed in 4 control wells without LPS.
Finally, cells were then imaged using an Olympus Fluoview 1000
Spectral Confocal (Olympus, Tokyo, Japan). Images of control and
sample wells were acquired using the same parameters.
2.4.3. Flow cytometry analysis
Cells were detached from each flask by using a non-enzymatic dis-
sociation buffer following manufacturer instructions (Accumax,
Thermo-Fischer, MA, USA). The use of trypsin-based methods was
avoided when cells were immediately tested afterwards due to the
possibility of rupture of membrane proteins such as VCAM-1 and ICAM-
1 compromising the antibody-target recognition. The cell suspension of
each flask was counted centrifuged (100 ×g for 5min) and adjusted to
1× 106 cells/mL in an Eppendorf tube to a final volume of 200 μL with
cold PBS-T. A total of 2 μg (10 μg/mL) of anti-VCAM-1 FITC monoclonal
antibody (Thermo-Fisher, MA, USA) were added to the VCAM-1 ana-
lysis group and 2 μg (10 μg/mL) ICAM-1 monoclonal Antibody Alexa
Fluor® 647 (Thermo-Fisher, MA, US) for the ICAM-1 analysis group to
the cell suspensions.
Once VCAM-1 and ICAM-1 expression was tested, endothelial cells
were incubated with nanoparticles at three different times: 1, 3 and 6 h.
Cells were then washed with PBS three times in order to remove non-
internalized particles. Cells were then lysed with RIPA cell lysis buffer
(Sigma-Aldrich, MO, USA), and the fluorescence of each well was
measured (Ex. 530 nm, Em. 546 nm) in a Tecan Spark 10M Multimode
Plate Reader (TECAN, ZSG, Switzerland). Absolute levels of fluores-
cence intensity cannot be compared between spheres and rods due to
the fluorophore bleaching during the rod stretching process. For this
purpose, data was normalized to 100% of the added dose. Wells without
particle washing (for each group) were used as positive controls and
considered as 100% of uptake. A control group without particles added
was used as a negative control to evaluate the cell background.
2.5. In vitro flow conditions nanoparticles accumulation
2.5.1. Microfluidic device architecture
Linear channel microfluidic devices (Cat # 101002) used in this
study were obtained from SynVivo, Inc. (Huntsville, AL). Each device
consisted of three linear 250 μm (width) and 100 μm (depth) channels.
Each channel was lined with brain endothelial cells and experienced
perfusion similar to physiological fluid flow conditions.
2.5.2. Cell culture
The immortalized human cerebral microvascular endothelial cell
line (hCMEC/D3) was obtained from Millipore Sigma and maintained
with EndoGRO-MV Complete Culture Media Kit supplemented with
1 ng/mL human animal-free basic fibroblast growth factor (bFGF-AF)
and 1% Penicillin-Streptomycin. Cells were cultured on collagen-coated
tissue culture flasks coated with 1:20 dilution of Corning® Collagen
Type I, Rat Tail, which was allowed to coat in the incubator for 1 h prior
to use. Cells were incubated at 37 °C, 95% humidity and 5% CO2 until
confluent. Cells were used between passage 27 and 36. For hCMEC/D3
culture microfluidic straight channels, human fibronectin (300 μg/mL)
was injected into each channel and allowed to incubate for 1 h at 37 °C
and 5% CO2. Channels were perfused with complete cell culture media.
To devoid the device from residual entrapped air, the device was
primed using inert N2 gas at 6 PSI for 30min. Devices were placed
inside a cell culture incubator prior to use. hCMEC/D3 grown to 70 to
80% confluency were trypsinized and resuspended in cell culture media
with increased serum concentration (10%). Cell suspension at 5×107
cells/mL was injected into the outer compartment at 6 μL/mL using a
Harvard Apparatus Pump 11 Pico Plus Elite and placed inside the in-
cubator upside down to facilitate attachment to the upper PDMS re-
gions of the channel. After sufficient cellular attachment, an identically
seeded flask of hCMEC/D3 cells was trypsinized, and cells were seeded
with the device in the upright position. Following cellular attachment,
channels were perfused with complete cell culture media at 5 μL/min.
Cells were fed daily by perfusion of the device with cell culture media
containing 10% FBS for the first day after seeding, and 5% FBS media
for each subsequent day.
To condition cells to physiological shear stresses, 5% FBS containing
media was injected according to a linear ramp profile (100 nL/min to
2.35 μL/min) over 12 h using a Harvard Apparatus PHD ULTRA™ with a
6×10 MultiRack attachment for multi-syringe perfusion. Constant
2.35 μL/min injection rate was maintained for at least 4 h. To induce an
inflammatory response, lipopolysaccharide (LPS) (1 μg/mL) was im-
mediately injected at a constant rate of 2.35 μL/min for 6 h prior to use.
Devices were inspected for any bubble formation and immediately used
for further studies.
2.5.3. Nanoparticle adhesion under flow
Once straight channel devices have been inflamed using LPS, 1-mL
syringes were loaded with the corresponding nanoparticle condition.
Nanoparticle solutions (5E10 NP/mL) were injected at 2.35 μL/min
(1.00 dyn/cm2) for 1 h. Channels were then perfused with DPBS before
and after being fixed with 4% PFA for 15min at room temperature.
Channels were imaged immediately using an Olympus Fluoview 1000
spectral confocal microscope to assess particle adhesion throughout the
channels. Relative particle intensities were analyzed and assessed using
ImageJ.
2.6. In vivo nanoparticle biodistribution after systemic inflammation
induction
To induce systemic inflammation, 30 g Swiss male mice of were
treated (i.v.) with LPS (100 μg/animal) [17–19] administered through
the jugular vein. Six hours after LPS treatment, systemic inflammation
was determined by mean IL-6 serum levels as a marker of inflammation
[20]. Once the LPS-mediated inflammation effect was confirmed (6 h
later), animals were treated i.v. through the jugular vein with tritium
labelled nanoparticles (15mg/kg, n=4 animals/group). The animal
control group was treated with vehicle (n=4). Six hours later, the
animals were perfused with 20mL of cold PBS, and brain, liver, spleen,
kidneys and lungs were removed, weighed, and homogenized by ul-
trasonication. A total of 50 μL of homogenized organ were pipetted into
two detection tubes (Kartell™ vials, PerkinElemer), 12mL of Supermix
OptiPhase detection cocktail (PerkinElmer, MA, USA) was added to
each tube, shaken until forming a homogeneous suspension, and im-
mediately measured the disintegrations per minute (DPM) in a scintil-
lation detector (Beckman Coulter LS6500 Liquid Scintillation Counter).
Prior to the sample measurement, the organs of 3 healthy animals were
measured without any radiation administration to evaluate the back-
ground produced. After analyzing the subsequent samples of the study,
the background corresponding to each organ was subtracted.
2.7. In vivo nanoparticle biodistribution after intracerebral inflammation
induction
To induce local inflammation in brain, LPS was administered in the
area of the striatum region [21,22]. A dose of LPS 10 μg/animal was
used in a volume of 4 μL. Systemic IL-6 serum levels were analyzed to
confirm that LPS was not causing systemic effect. Six hours after in-
tracerebral LPS injection, the animal brain was removed for subsequent
histological analysis.
2.7.1. Interleukin-6 (IL-6) analysis
Mice blood was extracted from the jugular vein, centrifuged at
1,700×g, and serum was collected. To confirm the systemic in-
flammation LPS-response, the serum levels of IL-6 were analyzed 6 h
after the induction (the maximum time point used in in vitro experi-
ments). In order to confirm that local LPS injection restricted the
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inflammation to the brain, IL-6 levels were analyzed in serum at 6 h and
24 h, by means of an IL-6 ELISA detection kit (LSbio, WA, USA).
2.7.2. Brain vessel immunostaining
Animals subjected to inflammatory induction were sacrificed 6 or
24 h after the stimulation (treated with either LPS 10 μg/animal or
saline). After follow-up period, the animals were transcardially per-
fused with 20mL of cold PBS. The brain was removed and quickly
cryopreserved into 10mL of isopentane (Merck, MA, USA) at −40 °C
was embedded in OCT resin (Tissue-Tek, Japan). For histological ana-
lysis, brain samples were sectioned in 12 μm thickness slices in a
cryostat (Tissue-Tek, Japan). The slides were washed with PBS for
15min thrice and incubated during 24 h with monoclonal anti-VCAM-1
1:200 (Biolegend, CA, USA) and anti-CD31 1:200 (Abcam, Cambridge,
UK) used as endothelial cell marker. After incubation, tissue samples
were washed (3×) with PBS and incubated again with a solution of
PBS-T and anti-rat 594 secondary antibody 1:400 (Thermo-Fischer,
USA), 488 Dylight Goat anti-Rabbit (Vector, CA, USA) with 5% (v/v) of
donkey and goat serum for 2 h at room temperature. Finally, slides
where washed again and incubated with Hoechst (Invitrogen, USA) for
nucleus staining. Microphotographs were taken using a Leica DMI 6000
B microscope with the LAS AF 1.0.0 software (Leica Microsystems,
Sweden).
2.7.3. qPCR of VCAM-1 in inflamed brain
For VCAM-1 qPCR analysis, the hemisphere where LPS was injected
was extracted and preserved at −80 °C. Then RNA extraction was
performed using a commercial column-based method (PureLinkTM
RNA Mini Kit, Invitrogen, USA) following manufacturer indications.
Reverse transcription mix was composed by 4 μL of reaction buffer (five
times), 2 μL of MgCl2 (2.5 mM in the final volume), 1 μL of dNTPs
(0.5 mM of each nucleotide in the final volume), and 1 μL of GoScript™
reverse transcriptase. The final reaction mix containing a total volume
of 20 μL was incubated 5min at 25 °C allowing annealing, and 60min at
42 °C allowing to extend the cDNA strand. After reverse transcription,
the product was diluted 1:5 in RNAse free water. Once concluded the
expression of VCAM was determined by q-PCR using β-Actin as a
control gene expression by means of GoTaq® qPCR masterMix
(Promega, WI, USA) and Mx3005P qPCR system (Agilent technologies,
CA, USA).
2.7.4. Statistical analysis
All data are presented as the mean and SD of the mean
(mean ± SD). The data were first examined to assess the distribution
using the D'Agostino and Pearson omnibus normality test. One-way or
2-way analysis of variance (ANOVA) followed by post hoc Bonferroni
evaluation was used to detect significant differences between the
groups. Statistical significance was set at p < .05. Animals were ran-
domly assigned to treatment groups, and researchers were blinded to
treatment administration, to treatments during particle accumulation
assessment, and during the analysis.
3. Results
3.1. In vitro and in vivo analysis of VCAM-1 and ICAM-1 expression
mediated by LPS
Immunological analysis showed that cells treated with LPS had in-
creased expression of VCAM-1 and ICAM-1 compared with control
groups (Fig. 1A) as well as by flow cytometry (Fig. 1B). Intensity ex-
pression ratio between cells stimulated with LPS and non-stimulated
cells (Fig. 1 C) reflected a 4.5-fold increase in the expression of ICAM-1,
whereas in the VCAM-1 group the ratio resulted in a 10-fold increase.
Based on these results, VCAM-1 protein was selected as the target for
the nanoparticles used in the in vitro and in vivo experiments. Over-
expression of VCAM-1 observed in previous in vitro experiments was
confirmed when experimental animals were treated i.v. with LPS
100 μg/animal as showed in the Fig. 2A by an immune-staining of
VCAM-1 6 h after inflammation induction. An increase of IL-6 serum
levels (Fig. 2B) confirmed the inflammatory response on VCAM-1 in-
duced by LPS treatment.
In order to induce a selective overexpression of VCAM-1 in brain
without causing a systemic inflammation in the whole animal body, LPS
was stereotaxically administered in the brain parenchyma.
Inmunohistological (Fig. 2A) and qPCR (Fig. 2C) analysis confirmed the
local expression of VCAM-1 in the brain region stimulated by LPS. Co-
localization of VCAM-1 and CD31 demonstrate the overexpression of
VCAM-1 was restricted to the vascular cells. Higher expression of
VCAM-1 was observed at 24 h after LPS injection. No significant blood
IL-6 release was observed with intracerebral LPS injection, confirming
inflammation was localized in the brain (Fig. 2B).
3.2. Nanoparticle design and functionalization
Once VCAM-1 was selected as the vascular target for both the in
vitro and in vivo model, fluorescent polystyrene spherical nanoparticles
of around 200 nm of diameter were stretched to rods with an aspect
ratio (AR) of 2. The stretching process was confirmed by SEM (Fig. 3 A
and B). Spheres surface of particles was 1.03× 105 nm2, while for rods
was 1.22×105 nm2, which represented an increase of 19.12% in the
surface area in rods respect to the spheres. To optimize the nanoparticle
functionalization, first a NH2-PEG-N3 (3.5 K) was incorporated to the
nanoparticle and N-(3-Dimetilaminopropil)-N′-etilcarbodiimida/N-Hy-
droxysuccinimide (EDC/NHS) reaction. A fluorescent PEG with a
terminal FITC group was first used to evaluate the percentage of PEG
incorporated to the particles. Around 20% of the total PEG was coupled
to the particles, we observed the same amount of PEG in both particles
(Fig. 3C), ensuring a full coverage of the surface as confirmed by Z-
potential. (Fig. 3F).
The antibody bioconjugation was performed on the azide groups of
the pegylated nanoparticles, this required first, to incorporate a
Dibenzocyclooctyne-amine (DBCO) molecule into the antibody. For this
reaction, the structure of the antibody was modified by means of an
oxidation with sodium periodate in the carbohydrate residues of the
constant region that generated aldehyde groups that reacted with of a
DBCO-amine molecule forming an imine bond. Once the antibody
structure was modified, the DBCO reacted with the azide groups of the
particles in a copper-free click reaction, binding covalently. The amount
of antibody (anti-VCAM-1 and control non-specific IgG form) coupled
to the particle was quantified my means of a Micro BCA assay (Fig. 3D).
The density of antibody corrected for area showed similar binning both
spherical and rod nanoparticles (Fig. 3E). Surface potential variation
after each reaction was measured by means of DLS confirming the an-
tibody coating in the nanoparticle surface (Fig. 3F).
3.3. Nanoparticle accumulation in static cell culture stimulated by LPS
Following the in vitro protocol established previously, endothelial
cells were stimulated for 6 h with LPS to induce the VCAM-1 expression
and treated with 50 μg (100 μg/mL) during 1, 3 and 6 h. Targeted
particles (both in spherical and rod nanoparticles) showed an increased
uptake compare to non-targeted in every time point under static cell
culture conditions (Fig. 4A). Although no statistical differences were
observed, targeted rods showed a higher trend in the accumulation
compared to targeted spheres. The difference is more evident when
correcting the unspecified accumulation of particles by establishing a
ratio between VCAM-1 targeted group and vehicle for both shapes
(Fig. 4B) and visualized by confocal microscopy (Fig. 4C and D).
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3.4. Nanoparticle binding assay under flow conditions in microfluidic
devices stimulated by LPS
The effect of nanoparticle shape on particle adhesion under flow
was evaluated with microfluidic channels (Fig. 5A) coupled to a mi-
croinjection pump to simulate shear stresses (1.00 dyn/cm2) as would
be found in vivo. Initially, microfluidic channels were lined with bEnd.3
cells, but to simulate a more translatable human blood brain barrier
(BBB) model, hCMEC/D3 cells were used for subsequent experiments
(Fig. 5B, Fig. 5C and Supplemental Video 1).
A total of 5×1010 nanoparticles/mL of particles were flown for 1 h
at 2.35 μL/min. Confocal slices of cell monolayers were analyzed at the
bottom of the channel (glass substrate) and the top of the channel
(PDMS substrate). Upon comparing particle geometries, no apparent
differences were observed between VCAM-1 targeted spheres and non-
specific IgG spheres (Fig. 5D and E). Both spherical particles had ac-
cumulated similarly in either case. However, more accumulation was
observed for VCAM-1 rod particles as compared with the non-specific
IgG rods (Fig. 5F), leading to greater targeting efficiency of rod-shaped
particles as compared to their spherical counterparts.
3.5. Analysis of nanoparticle biodistribution in animals subjected to LPS-
mediated systemic inflammation
Six hours after LPS administration, a dose of 15mg/kg of nano-
particles was administered i.v. in Swiss mice. After 6 h, the nanoparticle
biodistribution was assessed in various organs (brain, kidney, liver,
lungs and spleen) by analyzing the emitted radiation. VCAM-1 targeted
particles accumulated to a greater extent than the vehicle groups, while
no differences in the accumulation were observed between rod and
spherical shapes. Higher accumulation was observed in lungs with rod-
shaped VACM1 targeted particles. No differences were observed be-
tween the four groups tested in the other three organs analyzed
(Fig. 6A). Within the brain, no significant differences between shapes
Fig. 1. Analysis of the expression of VCAM-1 and ICAM-1 in vitro. (A) Immunofluorescence in bEnd.3 Control cells (without induction of inflammation) and
stimulated cells with different concentrations of LPS during 6 h. (B) Cytometric analysis of the expression of ICAM-1 and VCAM-1 in bEnd.3 control endothelial cells
and stimulated with LPS for 6 h. Blank group represents cells with no antibody labeling; non-inflamed group represents cells with no inflammation induction but
labelled for VCAM-1 or ICAM-1 and inflamed group represents cells with inflammation induction by means of LPS for 6 h and labelled with VCAM-1 or ICAM-1
antibody. Values in the table represents the average of Arbitrary Fluorescent Units (AFU). (C) Fold-increase of the expression of ICAM-1 and VCAM-1 in inflamed cells
with respect to the control group. Bars represent SD and * p < .05.
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was observed. Spherical particles showed a 1.2-fold increase in accu-
mulation in the targeted group compared to the control, while the rod-
shaped particle's accumulation was 1.4-fold compared to the respective
control group. The correction by unspecific accumulation establishing
the ratio targeted/vehicle shows that only in lung rod-shaped particles
presented higher accumulation (Fig. 6B). Raw biodistribution data are
included in supplmentary data (supplementary Fig. 1A).
3.6. Nanoparticle brain accumulation in animals subjected to local cerebral
inflammation induced by LPS
Previously, we saw an increase in VCAM-1 expression in the brain at
24 h after intracerebral LPS injection. Therefore, a 24 h time point was
used for nanoparticles treatment. The dose of nanoparticles was in-
creased to 30mg/kg (0.9 mg administered in 200 μL) to increase the
signal-to-noise ratio. Nanoparticles were administered intravenously
24 h after LPS stimulation. In this cerebral inflammation model, greater
accumulation of targeted particles was observed as compared to the
respective control groups regardless of the shape, suggesting the in-
creased accumulation was not due to non-specific particle accumulation
in the tissue (Fig. 7A). The average ratios between VACM-1 targeted
group/vehicle group were analyzed showing that spherical nano-
particles exhibited an uptake 3 times higher in the VCAM-1 group than
the control group, while animals treated with rod nanoparticles showed
an uptake 3.4 times higher for the VCAM1 group than the control group
(Fig. 7B), although the differences between both ratios were not sig-
nificant. Raw biodistribution data are included in supplmentary data
(Supplementary Fig. 1B).
4. Discussion
In this study we performed a longitudinal analysis of the effect of
nanoparticle shape on the accumulation in endothelial cells with tar-
geting VCAM-1 markers. Two shapes, polystyrene spheres and poly-
styrene rods with an aspect ratio of 2 were prepared. Previous literature
studies have shown that rod-shaped particles exhibit beneficial attri-
butes in terms of circulation times, biodistribution and cellular uptake
[10,23–25]. We first analyzed two endothelial markers as possible
targets for the NPs: the adhesion molecules ICAM-1 and VCAM-1 ex-
pressed on the luminal side of the endothelial cells. These markers were
chosen because of their inducible ability under inflammatory conditions
[26], increasing the number of copies expressed in the cell, and
Fig. 2. Inflammatory induction in vivo (A) Immunofluorescence staining of CD31 (green), VCAM-1 (Red) and nuclear staining (blue) in 12 μm brain slices of controls
and animals treated with LPS intravenous (100 μg/animal) and intracerebral (10 μg/animal). Microphotographs showed were acquired at 20× in vessels, white bar
represents 50 μm. (B) IL-6 levels in serum after administered 100 μg of LPS i.v. and i.p. in Swiss mice. (C) Quantification of the relative expression of VCAM1 in the
brain of control and inflamed animals by means of qPCR. The red line represents the basal expression of the controls without inflammatory stimulation. Bars
represent the average with SD and * p < .005 compared with the control group. (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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increasing the likelihood of binding interactions in pathological tissue
and not in the healthy state. Secondly, inflammation is a common oc-
currence in many neurological diseases such as ischemic and hemor-
rhagic stroke, Alzheimer's disease, multiple sclerosis, Parkinson's dis-
ease, and cancer [26–32]. Vascular inflammatory markers act as a
signaling point for circulating immune system cells, taking advantage of
this biological mechanism, these proteins can be used as anchors for
nanoparticles to treat or diagnose these pathologies more efficiently.
Inflammation was induced with LPS of E. coli, simulating an infection
without the need for the pathogen [33,34]. The expression of the
markers was analyzed by means of different methods throughout the
study in both in vitro and in vivo conditions. Initially, the expression of
the two markers (ICAM-1 and VCAM-1) was analyzed in cells of the
brain microvasculature of mouse (bEnd.3 cells) in a qualitative
Fig. 3. Nanoparticle characterizations. Scanning electron microscopy (SEM) images of spherical (A) and rod-shaped (B) polystyrene nanoparticles. C) Percentage of
PEG incorporated in the particles after the reaction. The values correspond to the average of 5 reactions, bars represent standard deviation. D) Number of anti
-VCAM1 antibodies coupled per particle, both in spheres and rods. Graphic show the means and SD of 5 separate antibody coupling reactions. E) VCAM-1 antibody
density expressed as μg of antibody per nm2 for spherical and rod-shaped particles. F) Variation of the zeta potential of spheres and rods after different surface
modifications obtained from DLS measurements. The values correspond to the average of 5 reactions. Bars represent average with SD.
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(immunostaining) and quantitative (flow cytometry) way, demon-
strating an increase in the expression of ICAM-1 (4.5-fold increase) and
in the VCAM-1 expression (around 10-fold increase) compared to the
non-inflamed cells. For this reason, we selected the VCAM-1 for nano-
particle targeting. VCAM-1 was also analyzed in vivo (in Swiss male
mice) after inflammation induction by qPCR showing a time-dependent
expression (8-fold increase after 24 h) and immunostaining (positive for
VCAM1 in brain vessels) confirming the overexpression in animal stu-
dies.
Polystyrene 200 nm spheres were stretched in one dimension into
rods with an aspect ratio of 2, and were functionalized with PEG and
antibodies against VCAM-1 endothelial receptor (a non-specific IgG
antibody was used as control). Particles targeted to VCAM-1 of each
shape were analyzed in comparison with particles coated with a non-
specific IgG (defined as control nanoparticles) and tested in different
conditions. We first analyzed the shape effect in static cell culture in
bEnd.3 cells. Specific spherical particles exhibited a 1.2- to 1.5-fold
increase in uptake compared to the control group (IgG-coated spherical
particles). Rods exhibited a greater enhancement of 2.1- to 2.5-fold over
corresponding controls. The images of confocal microscopy showed a
lower fluorescence intensity in the rod shaped-particles, which could
give the impression of a smaller accumulation of rods compared to the
sphere group. However, this effect is due to the spheres-to-rods
stretching process, since there is an important fluorescence bleaching
during this procedure and therefore cells incubated with rods showed
lower fluorescent intensity despite having the same concentration.
Images must be seen only as a reference to visualize the accumulation.
In order to make a valid comparison between the two shapes, a nor-
malization according to the administered dose or a ratio with the
VCAM/Vehicle group of each shape has been made along the work.
These results are in agreement with previous findings that rod-shaped
particles not only increase cellular uptake, but also increase specificity
of particle-cell interactions [35]. For rods, VCAM-1/control ratio
peaked at 3 h which is in agreement with similar studies, further sup-
porting the beneficial rod shape of nanoparticles for targeting cell
binding [15,36]. The ability of nanoparticles to adhere to cells and
surfaces under flow conditions was tested using microfluidic devices.
Microfluidic devices represent a comprehensive strategy to reproduce
shear stresses as would be found in vivo from the hemodynamic forces.
This allows for the induction of changes in endothelial morphology,
cytoskeletal remodeling, changes on gene expression, inducing a better
endothelial organization and reducing permeability, and mimicking the
in vivo vascular environment [37]. In this study, microfluidic devices
were used to evaluate if shear stress could alter the nanoparticles per-
formance, an approach that is increasingly included in the analysis of
nanoparticles where different flow rates are applied to evaluate their
effect on different nanostructures to bind to the endothelium [38,39].
Therefore, shear stress is an important parameter to take into account,
inversely related to the particle uptake [40]. The greater the shear
stress, the lower the probability of adhesion with the lumen target due
to the decoupling forces derived from the hydrodynamic forces [38,39].
To perform this study, bEnd.3 and hCMEC/d3 endothelial cells were
Fig. 4. In vitro nanoparticles accumulation in bEnd. 3 endothelial cells. A) Percentage of administered cell dose of vehicle (coated with no specific IgG antibody) and
VCAM1 targeted rods and spheres at different time points. B) Accumulation ratio between VCAM1 targeted particles and non-targeted in spheres and rods. Red line
represents the accumulation of the vehicle group. Bars represent average with SD and * p < .005 compared to the spherical shape. C) Confocal imaging of inflamed
Bend.3 endothelial cells nucleus (blue) treated with 50 μg of spherical and D) rod-shaped particles (red) at different time points (N=6 wells/group) after LPS
stimulation. Images were acquired at 20× white bars represents 100 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to
the web version of this article.)
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Fig. 5. A) Microfluidic device used to
perform the flow assays. B) Bright field
image of the central section of a micro-
fluidic chip coated with a monolayer of
hCMEC/D3 cells C) Three dimension re-
construction of a section of the micro-
fluidic circuit from images acquired in
confocal microscopy. Images acquired by
confocal microscopy of top and bottom
sections of microfluidic linear circuits
after the flow of (D) spherical and (E) rod-
shaped nanoparticles. Particles with the
same shape were acquired under the same
image conditions. F) Accumulation ratio
between VCAM targeted particles and
non-targeted in spheres and rods. Bars
represent the average with SD and *
p < .005 compared to the spheres group.
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selected because they represent two of the most used lines in BBB
models and brain tissue study as well, since they show a behavior very
similar to the microvasculature in physiological and pathological con-
ditions [41–45]. Similar systems have also been used to study nano-
particle penetration into tumors [46].
After flowing the particles for 1 h, no differences were observed in
binding of targeted spheres over non-targeted spheres. VCAM-1 rods, on
the other hand, exhibited a significant increase in binding under shear
stress. Similar studies analyzed the effect of shear stress showing a
drastic decrease in cell uptake when applying flow, decreasing pro-
portionally to the shear stress applied to the system [47]. When com-
paring shapes in static vs flow conditions, it can be observed that while
under static conditions there are obvious differences between targeted
and non-targeted in both shapes; when applying a shear stress of 1 dyn/
cm2, no difference in the uptake of spherical nanoparticles was ob-
served, while the rod targeted group maintained a significant difference
compared to the vehicle (1.7-fold increase). These findings suggest rod
shapes offer a clear advantage over the spheres in terms of cell binding.
Several factors may be responsible for this behavior including better
margination of rods, higher surface binding or reduced shear-induced
detachment. Indeed, these effects have been studied both in mathe-
matical models and experiments [48,49].
The translation of in vitro shape effects to in vivo conditions was
tested. The behavior of the particles can change significantly under in
vivo conditions due to different flow conditions, different caliber of
vessels and the trapping effect of immunological cells and organs as
kidney and liver that reduces the nanoparticles targeting efficacy. In
addition, when the nanoparticles are injected in an in vivo system, the
positive charge due to the antibody functionalization [50,51] leads to
electrostatic interactions with negatively charged blood proteins (de-
fined as protein corona) that can mask the targeting ability of nano-
particle in a dose-dependent manner [52] and it can also determine the
pathway when reached the cell [53].
Size and shape are important parameters that may determine the
composition of the protein corona [54]. To analyze the possible shape
effect in vivo of sphere and rods, VCAM-1 nanoparticles were injected in
systemically inflamed mice. No significant difference in particle accu-
mulation was found in liver, which could be attributed to the entrap-
ment in small vessels or capture for further processing without distin-
guishing between shapes or targeting. The kidneys contained a low
level of accumulation due to the size of this nanoparticles. On the
contrary, lungs showed a significant difference between shapes. Only
rods and not spheres, exhibited an increase in VCAM-1 group accu-
mulation compared with IgG group, which resembles the results
Fig. 6. A) Nanoparticle biodistribution ex vivo, in different organs after systemic inflammation induction. * indicates a p < .05 compared to vehicle group. B) Ratio
between VCAM /IgG media values of % Injected dose/g for spheres and rods. Red line represents the accumulation of the vehicle group. Bars represent the average
with SD and * p < .005, compared to the spherical shape. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version
of this article.)
A. Da Silva-Candal, et al. Journal of Controlled Release 309 (2019) 94–105
103
observed in microfluidic devices. Overall, the lung accumulation of rods
and spheres and its dependence on target specificity match well with
the results from in vitro microfluidic studies. In the brain, targeted
spheres as well as rods accumulated better than their non-targeted
controls, but the difference was not statistically different. This could
have potentially originated from the limitation of the detection or
binding of particles to non-analyzed inflamed regions.
In a second approach, we localized the inflammation in the brain by
local injection of LPS and observed a significant increase in the accu-
mulation of targeted particles compared to the controls. When com-
paring the shapes, the rods exhibited a slightly improved the accumu-
lation (3.5-fold) compared to the spheres (3-fold). These results are
consistent with the literature reports that elongated shapes exhibit
better targeting in the targeted zones compared to the spheres for
various materials including polystyrene, silica or iron [13,55,56]. Ad-
ministration route can also impact the outcome of nanoparticles, In-
travenous administration causes a significant loss of particles in off
target organs, while an intra-arterial administration of particles can
assist in localizing the drug to target organs [57]. The relatively small
difference between spheres and rods observed in this study can po-
tentially arise from several factors. First, the aspect ratio of rods used in
this study (AR ~2) is much smaller than those used previously
(AR~3–4). Hence, the contribution of shape, though clearly seen in in
vitro experiments, may be masked by the variability of the biological
systems. Adsorption of proteins in serum may further reduce the dif-
ferences in the shapes. Second, the antibody concentration on the sur-
face is lower in rods than in spheres, which may negate some of the
contribution of shape-enhanced binding. The stretching process in-
creased the surface area of the particles, but maintained the same
number of functional groups for the bioconjugation of the antibody,
which leads to a decrease of the surface density of ligands. This could
reduce the avidity of the particle for the target, influencing its specific
accumulation [58,59]. This study points to the potential existence of a
critical lower threshold of aspect ratio which is necessary to bring out
the difference between spheres and rods for in vivo brain targeting. This
issue should be addressed in future studies. Specifically, the nano-
particles with larger aspect ratios should be tested. Additional potential
benefits of elongated shapes including increase in the circulation times
[60,61] and change in interactions with cells [25,62] and greater pe-
netrance in the target organs especially in tumors [56,63] should be
explored in future studies.
5. Conclusions
In this study spherical (200 nm) and rod-shaped (400 nm length)
polystyrene particles were used to evaluate the shape effect when tar-
geting VCAM-1 in brain endothelial cells. The results demonstrate ac-
cumulation of VCAM-1-targeted rods to the endothelium under static
and flow conditions. The inducible nature of the target VCAM-1 under
inflammatory conditions limits unspecific accumulation with special
importance in neurological diseases with an inflammatory component.
Further studies should focus on optimization of parameters, especially
of the particle aspect ratio to elicit increased contribution of particle
aspherecity. Optimization of antibody conjugation to increase surface
density should also be performed to increase target specificity. Particles
prepared from biocompatible, biodegradable polymers with similar
dimensions should also be explored and designed to carry therapeutic
payloads. With further optimization, VCAM-1 targeted non-spherical
particles could open new therapeutic opportunities.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jconrel.2019.07.026.
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